Skip to content
2000
Volume 19, Issue 8
  • ISSN: 1386-2073
  • E-ISSN: 1875-5402

Abstract

Rosiglitazone was restricted clinically due to the side effects such as edema, weight gain and cardiac failure mainly attributing to the single and selective PPARγ activation. Nowadays, multi-targeted PPARs agonists remained to be a hot topic in the antidiabetic medicinal chemistry field. In this paper, the cooperative PPARα/γ dual agonists were screened from Specs database via the flow chart of docking, ADMET prediction and molecular dynamics (MD) simulations. Representative compounds ZINC36517927 and ZINC13573581 displayed higher binding scores, better pharmacokinetic profiles and were predicted to display the best binding affinity with PPARα/γ. Complex-based pharmacophore (CBP) models showed the key interactions in the PPARα/γ active sites. 20 ns simulations performed to the PPAR-ligand complexes indicated a stable binding conformation. This work provided an approach to identify novel high-efficiency PPARα/γ dual agonists for the treatment of type 2 diabetes mellitus (T2DM).

Loading

Article metrics loading...

/content/journals/cchts/10.2174/1386207319666160615013027
2016-09-01
2025-07-09
Loading full text...

Full text loading...

/content/journals/cchts/10.2174/1386207319666160615013027
Loading

  • Article Type:
    Research Article
Keyword(s): ADMET; CBP; MD simulations; molecular docking; PPARs; Specs database
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test